Fenofibrate and Metabolic Syndrome
Author(s): Aldi T. Kraja, Michael A. Province, Robert J. Straka, Jose M. Ordovas, Ingrid B. Borecki, Donna K. Arnett. Division of Statistical Genomics, Washington University School of Medicine, 4444 Forest Park Ave., Campus Box 8506, St. Louis, MO 63110, USA.
Journal Name: Endocrine, Metabolic & Immune Disorders - Drug Targets
The fibric acid derivative, fenofibrate (FF) has been used in the US since 1998 to manage patients with dyslipidemia. Typical changes in serum lipids as a result of FF treatment include clinically important mean reductions of serum triglycerides (TG) by a mean change of -93.7 mg/dL (-39.3%), increases of high density lipoprotein cholesterol (HDLC) by +5.5 mg/dL (+12.4%), and reductions in low density lipoprotein cholesterol (LDLC) by -17.9 mg/dL (-12.3%). The greatest reductions in serum TG are usually observed in subjects with elevated baseline TG including those with the metabolic syndrome (MetS). Although statins remain the mainstay of therapy for most dyslipidemic patients, their combined use with FF would be expected to address residual risk resulting from less than optimal TG and HDLC levels in such patients. Clinical trials examining the cardiovascular benefits of FF alone or combined with statins have produced mixed results. These observations underscore our lack of understanding of which patients may benefit from FF therapy and which do not. Although FFs basic mechanism of action is known to involve PPAR-α agonist activity resulting in altered transcription of several genes, the actual genetic bases for variability in lipid response is poorly understood. Studies, such as our GOLDN study and others were designed to better understand the genetic determinants of variability in the response to FF treatment and lipid levels. As a result several important genetic determinants of lipid levels have been identified. For example, in the GOLDN study SNPs from different genes were significantly associated with baseline lipid levels before treatment (APOA5- rs662799, rs3135506; APOC3- rs5128, rs2854117, rs4520); APOA4- rs5104; PPARArs9626730, rs135543, rs11703495; LPL- rs1801177), after treatment PPARA- rs11708495; LPL- rs1801177, and appeared to modulate overall response to FF treatment (NOS3- rs1799983). In this article, we will review the literature leading up to the contemporary use of FF as an agent to manage patients with dyslipidemia and focus on emerging understanding of the genetic variability in response to FF treatment. On the basis of the available evidence, we conclude that FF is of benefit in the treatment of dyslipidemia, especially among those with MetS. However, more work is needed to specifically identify which individuals derive a benefit from FF administration in terms of clinical outcomes and which do not - particularly in the context of type 2 diabetes.
Keywords: Fenofibrate, clinical trials, lipids, metabolic syndrome, single nucleotide polymorphism, random coefficients model, multivariate analysis
Title: Fenofibrate and Metabolic Syndrome
Author(s):Aldi T. Kraja, Michael A. Province, Robert J. Straka, Jose M. Ordovas, Ingrid B. Borecki and Donna K. Arnett
Affiliation:Division of Statistical Genomics, Washington University School of Medicine, 4444 Forest Park Ave., Campus Box 8506, St. Louis, MO 63110, USA.
Keywords:Fenofibrate, clinical trials, lipids, metabolic syndrome, single nucleotide polymorphism, random coefficients model, multivariate analysis
Abstract: The fibric acid derivative, fenofibrate (FF) has been used in the US since 1998 to manage patients with dyslipidemia. Typical changes in serum lipids as a result of FF treatment include clinically important mean reductions of serum triglycerides (TG) by a mean change of -93.7 mg/dL (-39.3%), increases of high density lipoprotein cholesterol (HDLC) by +5.5 mg/dL (+12.4%), and reductions in low density lipoprotein cholesterol (LDLC) by -17.9 mg/dL (-12.3%). The greatest reductions in serum TG are usually observed in subjects with elevated baseline TG including those with the metabolic syndrome (MetS). Although statins remain the mainstay of therapy for most dyslipidemic patients, their combined use with FF would be expected to address residual risk resulting from less than optimal TG and HDLC levels in such patients. Clinical trials examining the cardiovascular benefits of FF alone or combined with statins have produced mixed results. These observations underscore our lack of understanding of which patients may benefit from FF therapy and which do not. Although FFs basic mechanism of action is known to involve PPAR-α agonist activity resulting in altered transcription of several genes, the actual genetic bases for variability in lipid response is poorly understood. Studies, such as our GOLDN study and others were designed to better understand the genetic determinants of variability in the response to FF treatment and lipid levels. As a result several important genetic determinants of lipid levels have been identified. For example, in the GOLDN study SNPs from different genes were significantly associated with baseline lipid levels before treatment (APOA5- rs662799, rs3135506; APOC3- rs5128, rs2854117, rs4520); APOA4- rs5104; PPARArs9626730, rs135543, rs11703495; LPL- rs1801177), after treatment PPARA- rs11708495; LPL- rs1801177, and appeared to modulate overall response to FF treatment (NOS3- rs1799983). In this article, we will review the literature leading up to the contemporary use of FF as an agent to manage patients with dyslipidemia and focus on emerging understanding of the genetic variability in response to FF treatment. On the basis of the available evidence, we conclude that FF is of benefit in the treatment of dyslipidemia, especially among those with MetS. However, more work is needed to specifically identify which individuals derive a benefit from FF administration in terms of clinical outcomes and which do not - particularly in the context of type 2 diabetes.
Aldi T. Kraja, Michael A. Province, Robert J. Straka, Jose M. Ordovas, Ingrid B. Borecki and Donna K. Arnett, " Fenofibrate and Metabolic Syndrome", Endocrine, Metabolic & Immune Disorders - Drug Targets (2010) 10: 138. https://doi.org/10.2174/187153010791213047
Nutritional Interventions and Primary Prevention of Type 2 Diabetes
Current Nutrition & Food Science
Monoclonal Antibodies: New Therapeutic Agents for Autoimmune Hemolytic Anemia?
SHIP2: An Emerging Target for the Treatment of Type 2 Diabetes Mellitus
Current Drug Targets - Immune, Endocrine & Metabolic Disorders
Immunomodulatory and Anti-Inflammatory Activities of Statins
An Unusual Case of Medullary Thyroid Carcinoma and A Revision of Current Literature
PPAR Activity in the Vessel Wall: Anti-Atherogenic Properties
Estrogen Receptor-α: Plasma Membrane Localization and Functions
Targets of Anti-glucocorticoid Therapy for Stress-related Diseases
Recent Patents on CNS Drug Discovery (Discontinued)
Anti-Angiogenesis Drugs in Diabetic Retinopathy
Current Pharmaceutical Biotechnology
Insulin-Sensiting Effects of Tumor Necrosis Factor Alpha Inhibitors in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Reviews on Recent Clinical Trials
Time Recall; Future Concept of Chronomodulating Chemotherapy for Cancer
Cardiac Fat as New Diagnostic Tool and Potential Therapeutic Target for Obesity Management and Treatment
Beta3 -Adrenoceptor Agonists as Anti-diabetic and Anti-obesity Drugs in Humans
Metabolic Syndrome and Aging: Calcium Signaling as Common Regulator
Correlation of Urine Biomarkers: Microalbuminuria and Spot Urine Protein among Diabetic Patients. Application of Spot Urine Protein in Diabetic Kidney Disease, Nephropathy, Proteinuria Estimation, Diagnosing and Monitoring
Indications, Implications and Applications of Renal Denervation. Have we Discovered Something new?
Current Hypertension Reviews
Metabolic and Cardiovascular Complications of Highly Active Antiretroviral Therapy for HIV Infection
Current HIV Research
Selective Divalent Copper Chelation for the Treatment of Diabetes Mellitus
Peroxynitrite-Driven Mechanisms in Diabetes and Insulin Resistance – the Latest Advances
Viral Infection and Obesity: Current Status and Future Prospective